EA201791095A1 - Способ лечения рака - Google Patents

Способ лечения рака

Info

Publication number
EA201791095A1
EA201791095A1 EA201791095A EA201791095A EA201791095A1 EA 201791095 A1 EA201791095 A1 EA 201791095A1 EA 201791095 A EA201791095 A EA 201791095A EA 201791095 A EA201791095 A EA 201791095A EA 201791095 A1 EA201791095 A1 EA 201791095A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment method
cancer treatment
inhibitor
ezh2
methods
Prior art date
Application number
EA201791095A
Other languages
English (en)
Inventor
Хайке Кайльхак
Бретт Труитт
Юта Сузуки
Цукаса Мурасе
Футоси Сиката
Original Assignee
Эпизайм, Инк.
ЭИСАИ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпизайм, Инк., ЭИСАИ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. filed Critical Эпизайм, Инк.
Publication of EA201791095A1 publication Critical patent/EA201791095A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Изобретение относится к фармацевтическим композициям, содержащим ингибитор(ы) гистонметилтрансферазы EZH2 человека, и способам терапии рака с применением ингибитора(ов) EZH2.
EA201791095A 2014-11-17 2015-11-17 Способ лечения рака EA201791095A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462080985P 2014-11-17 2014-11-17
US201562166572P 2015-05-26 2015-05-26
US201562251903P 2015-11-06 2015-11-06
PCT/US2015/061194 WO2016081523A1 (en) 2014-11-17 2015-11-17 Method for treating cancer

Publications (1)

Publication Number Publication Date
EA201791095A1 true EA201791095A1 (ru) 2017-10-31

Family

ID=56014476

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791095A EA201791095A1 (ru) 2014-11-17 2015-11-17 Способ лечения рака

Country Status (21)

Country Link
US (2) US10786511B2 (ru)
EP (2) EP4272742A1 (ru)
JP (3) JP6829684B2 (ru)
KR (3) KR102644844B1 (ru)
CN (2) CN107249591B (ru)
AU (3) AU2015350108B2 (ru)
BR (1) BR112017010166A2 (ru)
CA (1) CA2967664A1 (ru)
DK (1) DK3220916T3 (ru)
EA (1) EA201791095A1 (ru)
ES (1) ES2947819T3 (ru)
FI (1) FI3220916T3 (ru)
HU (1) HUE062159T2 (ru)
IL (3) IL296080B2 (ru)
LT (1) LT3220916T (ru)
MX (2) MX2017006089A (ru)
PL (1) PL3220916T3 (ru)
PT (1) PT3220916T (ru)
SG (1) SG11201703806XA (ru)
SI (1) SI3220916T1 (ru)
WO (1) WO2016081523A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282741B2 (en) 2013-12-06 2024-01-01 Epizyme Inc Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer
MX2021007651A (es) 2014-06-17 2021-08-11 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.
AU2015350108B2 (en) 2014-11-17 2021-04-08 Eisai R&D Management Co., Ltd. Method for treating cancer
EA201792304A1 (ru) 2015-04-20 2018-03-30 Эпизайм, Инк. Комбинированная терапия для лечения рака
CN107635965A (zh) 2015-06-10 2018-01-26 Epizyme股份有限公司 用于治疗淋巴瘤的ezh2抑制剂
US10493076B2 (en) 2015-08-24 2019-12-03 Epizyme, Inc. Method for treating cancer
AU2017211331A1 (en) 2016-01-29 2018-06-07 Epizyme, Inc. Combination therapy for treating cancer
WO2017210395A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
WO2017218953A1 (en) 2016-06-17 2017-12-21 Epizyme, Inc. Ezh2 inhibitors for treating cancer
US11311524B2 (en) 2017-01-19 2022-04-26 Daiichi Sankyo Company, Limited Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
JP2020522687A (ja) 2017-06-02 2020-07-30 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
JP7399079B2 (ja) 2017-09-05 2023-12-15 エピザイム，インコーポレイティド 癌を処置するための併用療法
BR112022012258A2 (pt) * 2019-12-20 2022-08-30 Epizyme Inc Sal cristalino de bromidreto de um inibidor de ezh2, sua preparação e composição farmacêutica útil para o tratamento de câncer
JP2022167451A (ja) 2021-04-23 2022-11-04 日立Astemo株式会社 情報処理装置、情報処理方法、プログラムおよび記憶媒体
WO2023159124A2 (en) * 2022-02-17 2023-08-24 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
WO2023209591A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070026064A1 (en) * 2005-07-29 2007-02-01 Yoder Steven L Pharmaceutical dosage forms having watermark-type identification and authentication inditia
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP2614369B1 (en) 2010-09-10 2016-02-03 Epizyme, Inc. Method for determining the suitability of inhibitors of human ezh2 in treatment
EP2663283B1 (en) * 2011-01-14 2017-05-10 Bristol-Myers Squibb Company High drug load tablet formulation of brivanib alaninate
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EP3536314A1 (en) * 2012-03-12 2019-09-11 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
IL289300B2 (en) * 2012-04-13 2024-05-01 Epizyme Inc Combined treatment for cancer
BR112014025508B1 (pt) * 2012-04-13 2020-11-17 Eisai R&D Management Co., Ltd. forma de sal de um inibidor de histona metiltransferase ezh2 humana
HUE046790T2 (hu) * 2012-10-15 2020-03-30 Epizyme Inc A rák kezelésének módszerei
MY180311A (en) 2012-10-15 2020-11-28 Epizyme Inc Substituted benzene compounds
EP2934531A4 (en) * 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
EP2935264B1 (en) 2012-12-21 2017-10-18 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
CA2894216A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS CONDENSED IN 6.5
WO2014172044A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
EP4324525A3 (en) * 2013-10-16 2024-07-17 Epizyme, Inc. Hydrochloride salt form for ezh2 inhibition
JP2016533364A (ja) 2013-10-18 2016-10-27 エピザイム，インコーポレイティド 癌を処置する方法
IL282741B2 (en) 2013-12-06 2024-01-01 Epizyme Inc Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer
MX2021007651A (es) * 2014-06-17 2021-08-11 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.
WO2015200650A1 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
CA2963149A1 (en) 2014-10-16 2016-04-21 Epizyme, Inc. Method for treating cancer
AU2015350108B2 (en) 2014-11-17 2021-04-08 Eisai R&D Management Co., Ltd. Method for treating cancer
CN107635965A (zh) * 2015-06-10 2018-01-26 Epizyme股份有限公司 用于治疗淋巴瘤的ezh2抑制剂
WO2017218953A1 (en) * 2016-06-17 2017-12-21 Epizyme, Inc. Ezh2 inhibitors for treating cancer

Also Published As

Publication number Publication date
KR102338802B1 (ko) 2021-12-14
KR20210156840A (ko) 2021-12-27
IL252182B2 (en) 2023-02-01
HUE062159T2 (hu) 2023-10-28
CA2967664A1 (en) 2016-05-26
IL296080B1 (en) 2023-08-01
US20210060030A1 (en) 2021-03-04
AU2021204706B2 (en) 2023-11-23
IL296080A (en) 2022-11-01
BR112017010166A2 (pt) 2018-02-14
KR20240035908A (ko) 2024-03-18
US20170360797A1 (en) 2017-12-21
IL252182B (en) 2022-10-01
IL252182A0 (en) 2017-07-31
PL3220916T3 (pl) 2023-08-14
IL296080B2 (en) 2023-12-01
MX2021006734A (es) 2021-07-02
EP3220916A4 (en) 2018-07-11
JP2017537899A (ja) 2017-12-21
CN107249591A (zh) 2017-10-13
KR20170103768A (ko) 2017-09-13
IL304252A (en) 2023-09-01
EP3220916B1 (en) 2023-04-19
FI3220916T3 (fi) 2023-06-19
EP4272742A1 (en) 2023-11-08
LT3220916T (lt) 2023-07-25
ES2947819T3 (es) 2023-08-21
AU2015350108B2 (en) 2021-04-08
JP2023062189A (ja) 2023-05-02
JP7485810B2 (ja) 2024-05-16
AU2024201171A1 (en) 2024-03-14
SI3220916T1 (sl) 2023-09-29
AU2021204706A1 (en) 2021-07-29
KR102644844B1 (ko) 2024-03-07
US10786511B2 (en) 2020-09-29
EP3220916A1 (en) 2017-09-27
NZ731696A (en) 2024-03-22
DK3220916T3 (da) 2023-06-26
JP2021073241A (ja) 2021-05-13
JP6829684B2 (ja) 2021-02-10
CN107249591B (zh) 2024-01-30
SG11201703806XA (en) 2017-06-29
CN116650500A (zh) 2023-08-29
MX2017006089A (es) 2017-12-11
WO2016081523A1 (en) 2016-05-26
PT3220916T (pt) 2023-06-26
AU2015350108A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
EA201791095A1 (ru) Способ лечения рака
EA201890567A1 (ru) Способ лечения рака
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
MX2020003702A (es) Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1).
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201791874A1 (ru) Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
EA201591599A1 (ru) Ингибиторы ido
EA201691134A1 (ru) Новые ингибиторы глутаминазы
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
GB2541571A (en) Pharmaceutical compositions
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201992137A1 (ru) ПИРИМИДОПИРИМИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ Wee-1
PH12018502154A1 (en) Methods of treating ocular conditions
EA201790565A1 (ru) Композиции и способы для лечения предраковых поражений кожи
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
ZA201703467B (en) Methods of treating ocular conditions